Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19151517 | 0.83 | HCRTR2 (0.50) | HCRTR2HCRTR1 | |
| SCHEMBL264270 | 0.83 | HCRTR2 (0.50) | HCRTR2HCRTR1 | |
| SCHEMBL30775045 | 0.83 | HCRTR2 (0.50) | HCRTR2HCRTR1 | |
| SCHEMBL30775080 | 0.83 | L3MBTL1 (0.49) | HCRTR2HCRTR1 | |
| SCHEMBL607604 | 0.83 | L3MBTL1 (0.49) | HCRTR2HCRTR1 | |
| SCHEMBL607037 | 0.82 | HCRTR2 (0.49) | HCRTR2HCRTR1 | |
| Lithium SCHEMBL607039 | 0.82 | HCRTR2 (0.49) | HCRTR2HCRTR1 | |
| Lithium Ion SCHEMBL2501474 | 0.76 | HCRTR1 (0.43) | HCRTR2HCRTR1 | |
| SCHEMBL31336716 | 0.73 | HCRTR2 (0.42) | HCRTR2HCRTR1 | |
| Lithium Ion SCHEMBL28358276 | 0.73 | CASP6 (0.39) | HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024509-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | C4X DISCOVERY LIMITED (GB) | 2024-07-02 | — | — | US | disclosed |
| EP-3189043-B1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | C4X DISCOVERY LTD (GB) | 2020-11-18 | — | — | EP | disclosed |
| US-20200270247-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | C4X DISCOVERY LIMITED | 2020-08-27 | — | — | US | disclosed |
| US-10611760-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | C4X DISCOVERY LIMITED (GB) | 2020-04-07 | — | — | US | disclosed |
| US-20170291897-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | INDIVIOR INC. | 2017-10-12 | — | — | US | disclosed |
| EP-3189043-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | C4x Discovery Limited (GB) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016034882-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | C4X DISCOVERY LIMITED (GB) | 2016-03-10 | — | — | WO | disclosed |
| WO-2012089607-A1 | NOVEL COMPOUNDS WITH A 3A-AZABICYCLO [4.1.0] HEPTANE CORE ACTING ON OREXIN RECEPTORS | GLAXO GROUP LIMITED (GB) | 2012-07-05 | — | — | WO | disclosed |
| EP-2421850-A1 | 3 -AZABICYCLO [4.1.0]HEPTANES USED AS OREXIN ANTAGONISTS | Glaxo Group Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| EP-2379550-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | Glaxo Group Limited (GB) | 2011-10-26 | — | — | EP | disclosed |
| US-20110257198-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2011-10-20 | — | — | US | disclosed |
| WO-2010122151-A1 | 3 -AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010072722-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-07-01 | — | — | WO | disclosed |
| US-20100144760-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024509-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | HCRTR1, HCRTR2, NPY1R | HCRTR2 2/4885HCRTR1 1/4885 |
| US-20200270247-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | HCRTR1, HCRTR2, NPY1R | HCRTR2 2/4885HCRTR1 1/4885 |
| US-20110257198-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, VIPR2 | HCRTR2 1/4885HCRTR1 2/4885 |
| US-10611760-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | HCRTR1, HCRTR2, NPY1R | HCRTR2 2/4885HCRTR1 1/4885 |
| US-20170291897-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | HCRTR1, HCRTR2, NPY1R | HCRTR2 2/4885HCRTR1 1/4885 |
| US-20100144760-A1 | NOVEL COMPOUNDS | HTR3B, HTR1B, HTR2B | HCRTR2 1425/4885HCRTR1 2016/4885 |
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | HCRTR2 1/4885HCRTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.